JP2023526428A5 - - Google Patents
Info
- Publication number
- JP2023526428A5 JP2023526428A5 JP2022570534A JP2022570534A JP2023526428A5 JP 2023526428 A5 JP2023526428 A5 JP 2023526428A5 JP 2022570534 A JP2022570534 A JP 2022570534A JP 2022570534 A JP2022570534 A JP 2022570534A JP 2023526428 A5 JP2023526428 A5 JP 2023526428A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protease
- antigen
- subunit
- life extension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025227145A JP2026031678A (ja) | 2020-05-19 | 2025-12-03 | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027276P | 2020-05-19 | 2020-05-19 | |
| US63/027,276 | 2020-05-19 | ||
| PCT/US2021/033014 WO2021236676A1 (en) | 2020-05-19 | 2021-05-18 | Activatable il-12 polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025227145A Division JP2026031678A (ja) | 2020-05-19 | 2025-12-03 | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526428A JP2023526428A (ja) | 2023-06-21 |
| JP2023526428A5 true JP2023526428A5 (enExample) | 2024-05-24 |
Family
ID=76375661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570534A Pending JP2023526428A (ja) | 2020-05-19 | 2021-05-18 | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
| JP2025227145A Pending JP2026031678A (ja) | 2020-05-19 | 2025-12-03 | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025227145A Pending JP2026031678A (ja) | 2020-05-19 | 2025-12-03 | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043488A1 (enExample) |
| EP (1) | EP4153612A1 (enExample) |
| JP (2) | JP2023526428A (enExample) |
| KR (1) | KR20230012564A (enExample) |
| CN (1) | CN116096738A (enExample) |
| AU (1) | AU2021276337A1 (enExample) |
| BR (1) | BR112022023288A2 (enExample) |
| CA (1) | CA3178657A1 (enExample) |
| IL (1) | IL298295A (enExample) |
| MX (1) | MX2022014411A (enExample) |
| WO (1) | WO2021236676A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| WO2021016599A1 (en) * | 2019-07-25 | 2021-01-28 | Trutino Biosciences Inc | Il-2 cytokine prodrugs comprising a cleavable linker |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| US20250114489A1 (en) | 2022-02-15 | 2025-04-10 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
| WO2023196897A1 (en) * | 2022-04-07 | 2023-10-12 | Werewolf Therapeutics Inc. | Il-12 prodrugs |
| WO2024124164A2 (en) * | 2022-12-09 | 2024-06-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells |
| AR131624A1 (es) * | 2023-01-18 | 2025-04-16 | Chugai Pharmaceutical Co Ltd | Citoquina activada por proteasa |
| WO2024211877A2 (en) * | 2023-04-06 | 2024-10-10 | Werewolf Therapeutics, Inc. | Il-12 prodrugs, methods of use and pharmaceutical compositions |
| WO2025072450A1 (en) | 2023-09-26 | 2025-04-03 | Werewolf Therapeutics, Inc. | Enhanced adoptive cell therapy |
| WO2026072455A1 (en) | 2024-09-26 | 2026-04-02 | Werewolf Therapeutics, Inc. | Single domain human serum albumin antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110728A2 (en) | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Immunogenic cmv tegument aggregates |
| US10696722B2 (en) * | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| US10472816B2 (en) | 2017-07-26 | 2019-11-12 | Justin Griebel | Backflow valve assembly |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20220002370A1 (en) * | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| AU2020353235A1 (en) * | 2019-09-28 | 2022-03-31 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| JP7773991B2 (ja) * | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
-
2021
- 2021-05-18 CA CA3178657A patent/CA3178657A1/en active Pending
- 2021-05-18 WO PCT/US2021/033014 patent/WO2021236676A1/en not_active Ceased
- 2021-05-18 KR KR1020227044128A patent/KR20230012564A/ko active Pending
- 2021-05-18 IL IL298295A patent/IL298295A/en unknown
- 2021-05-18 AU AU2021276337A patent/AU2021276337A1/en active Pending
- 2021-05-18 EP EP21731656.1A patent/EP4153612A1/en active Pending
- 2021-05-18 BR BR112022023288A patent/BR112022023288A2/pt unknown
- 2021-05-18 CN CN202180049641.4A patent/CN116096738A/zh active Pending
- 2021-05-18 MX MX2022014411A patent/MX2022014411A/es unknown
- 2021-05-18 JP JP2022570534A patent/JP2023526428A/ja active Pending
-
2022
- 2022-11-11 US US18/054,601 patent/US20240043488A1/en active Pending
-
2025
- 2025-12-03 JP JP2025227145A patent/JP2026031678A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526428A5 (enExample) | ||
| JP2019513014A5 (enExample) | ||
| JP2021087429A5 (enExample) | ||
| US20250163153A1 (en) | Release segments and binding compositions comprising same | |
| JP7490853B2 (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| US20220017640A1 (en) | Activatable bispecific antibodies | |
| JP2023547978A5 (enExample) | ||
| US20210355219A1 (en) | Conditionally activated target-binding molecules | |
| US20220267400A1 (en) | Il-2 cytokine prodrugs comprising a cleavable linker | |
| JP7707360B2 (ja) | 拘束され、条件的に活性化された結合タンパク質 | |
| JP2023552812A5 (enExample) | ||
| JP2022513888A5 (enExample) | ||
| CN116655799A (zh) | 包括可切割接头的il-2细胞因子前药 | |
| JP2023540533A (ja) | ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物 | |
| CN115003693A (zh) | 多肽、蛋白质复合物及其制造方法 | |
| US20240327538A1 (en) | Compositions targeting prostate-specific membrane antigen and methods for making and using the same | |
| US12590159B2 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| JP2025511713A5 (enExample) | ||
| JP2025511187A5 (enExample) | ||
| JP2024542978A5 (enExample) | ||
| JP2025511190A5 (enExample) | ||
| CN118556074A (zh) | 接头多肽 | |
| JP2024531338A5 (enExample) | ||
| JP2024531338A (ja) | 活性化可能インターフェロンポリペプチド及びその使用方法 | |
| JPWO2023068377A5 (enExample) |